Judges Scientific slips 11% as order book weakens and US outlook dims

Judges Scientific shares fell 11% to 5,100p after the AIM-listed specialist warned of a weaker-than-desired order book and dimming US demand: organic order intake fell 6% in 2025 and the organic order book covered 15.7 weeks of sales, down from 18.7 weeks. Adjusted EPS for 2025 is expected around 275p (about 6% below market expectations) and 2026 guidance was cut to 200–250p assuming no US rebound and no contribution from Geotek’s coring (now delayed to 2027); the group has moved to reduce costs and focus on international growth. Investors should note the near-term earnings downgrade, exposure to a soft US market and weaker offshore-wind investment as key downside risks to the stock.

Analysis

Market structure: Judges (AIM:JDG) deterioration (order book 18.7→15.7 weeks; organic intake -6% in 2025) favors larger, diversified scientific-instrument and consumables players (Thermo Fisher TMO, Agilent A, Waters WAT) that have broader service/recurring revenues and US exposure hedged by scale. Niche OEM suppliers tied to offshore-wind coring and episodic field work are losers as capex timing shifts; pricing power for small acquirers weakens if customers delay projects. Cross-asset: a sustained US slowdown risks small-cap AIM illiquidity and raises idiosyncratic equity vol; FX (USD/GBP) moves will amplify reported revenues for UK exporters while global copper/steel demand could soften if offshore wind spend remains weak.

Risk assessment: Key tail risks include a deeper US R&D pullback (20%+ reduction in project starts), further Geotek expedition delays to 2028, or a sharp AIM market repricing that impairs acquisition finance. Immediate (days) risk is sentiment-led share drops; short-term (weeks/months) risk is order-book deterioration; long-term (quarters) is impaired organic growth and more aggressive cost cuts or dilutive M&A. Hidden dependency: revenue bump from Geotek is binary and already excluded from 2026 guidance, so FY26 earnings hinge on margin actions and US demand recovery. Catalysts: US federal R&D budget signals (next 60–180 days), Q1 order intake release, and Geotek timetable updates.

Trade implications: Short-biased direct play on JDG: favorable risk/reward because guidance midpoint 225p vs market expectations implies earnings risk; prefer a tactical short (or put spread) sized 2–4% of portfolio with target 4,200–4,500p and stop 5,500p. Pair trade: long HLMA.L (2–3%) or TMO (1–2%) vs short JDG to capture defensive rotation and scale advantage. Options: buy a 3-month JDG put spread (5,000p/4,000p) to cap cost while harvesting downside if order weeks slip below 14. Sector rotation: reduce small-cap specialist instrument exposure and increase large-cap lab-consumables for 6–12 months.

Contrarian angles: The market may be over-penalising JDG for a temporary US timing issue — guidance already assumes no US rebound and no Geotek contribution, so a stabilization of order intake (return to -2% y/y) or a political push for R&D within 90–180 days could trigger a sharp re-rating. Mispricing risk: if order book stabilizes above 16.5 weeks or EPS revises back toward 250–275p, short squeezes are possible. Unintended consequence of aggressive cost cuts: service capacity erosion leading to longer-term share loss, making a selective short more attractive than a blunt small-cap sector underweight.

Key Decisions for Investors

• Establish a tactical 3% portfolio short in Judges Scientific (AIM:JDG) via stock or CFD at market (~5,100p), target 4,200–4,500p (18–22% downside) with a hard stop-loss at 5,500p; reassess at Q1 order-intake release or if order book >16.5 weeks.
• Implement a 1–2% long in Thermo Fisher (NYSE:TMO) or Agilent (NYSE:A) as a hedge and play on potential US R&D funding normalization, horizon 6–12 months; scale in on any ≤10% pullback and trim into strength above +15%.
• Execute a limited-cost options trade: buy a 3-month JDG put spread (long 5,000p short 4,000p) sized to 1% portfolio risk to capture downside if order weeks drop below 14 within 90 days.
• Pair trade: Long 2–3% Halma (LSE:HLMA) (defensive industrial/medical tech) and short 3% JDG to capture relative strength; rebalance if HLMA outperforms JDG by >10% or if JDG order intake improves to >17 weeks.
• Trigger-based monitoring: if JDG organic intake falls >10% y/y or order book drops below 14 weeks within 60 days, increase short to 5% or roll puts further out; if US federal R&D announcements signal >5% incremental funding within 180 days, close shorts and redeploy 50% into TMO/A longs.